UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000038760
Receipt number R000043619
Scientific Title Study of the immunogenicity of 13-valent pneumococcal conjugate vaccine in high-risk patients who were outside recommended ages for routine vaccination
Date of disclosure of the study information 2019/12/02
Last modified on 2022/06/08 15:22:06

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Study of the immunogenicity of 13-valent pneumococcal conjugate vaccine in high-risk patients who were outside recommended ages for routine vaccination

Acronym

Study of the immunogenicity of PCV13 in high-risk patients

Scientific Title

Study of the immunogenicity of 13-valent pneumococcal conjugate vaccine in high-risk patients who were outside recommended ages for routine vaccination

Scientific Title:Acronym

Study of the immunogenicity of PCV13 in high-risk patients

Region

Japan


Condition

Condition

hematological malignancies and post hematopoietic stem cell transplantations

Classification by specialty

Hematology and clinical oncology Infectious disease Pediatrics

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To invastigate about immunogenicity of 13-valent pneumococcal conjugate vaccine in high-risk patients such as hematological malignancies and post hematopoietic stem cell transplantations who were outside recommended ages for routine vaccination

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

We investigate the following three immunological markers before and 1 month, 6 months, 12 months after PCV13 vaccinations.

1. pneumococcal serotype specific IgG concentrations against serotypes which are present in PCV13.
2. pneumococcal serotype specific opsonophagocytic killing assay titers against serotypes which are present in PCV13.
3. the number of pneumococcal serotype specific memory B cells against serotypes which are present in PCV13.

Key secondary outcomes

1. the number of leukocyte and lymphocyte (before and 1 month, 6 months, 12 months after PCV13 vaccinations)
2. serum IgG consentrations and IgG subclasses (before and 12 months after PCV13 vaccinations)
3. pneumococcal detection from nasopharyngeal swab or saliva (before and 12 months after PCV13 vaccinations)
4. the incidence of adverse effects (1 month after PCV13 vaccinations)
5. the incidence of invasive pneumococcal diseases (12 months after PCV13 vaccinations)


Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

6 years-old <=

Age-upper limit

65 years-old >

Gender

Male and Female

Key inclusion criteria

Patients aged 6-64 years old who have underlying diseases such as hematological malignancies, and post hematopoietic stem cell transplantation.
Patients with prior written consents of PCV13 vaccination suggested from their attending doctor.

Key exclusion criteria

Patients who were determined as unsuitable subjects by investigators.

Target sample size

50


Research contact person

Name of lead principal investigator

1st name Naruhiko
Middle name
Last name Ishiwada

Organization

Medical Mycology Research Center, Chiba University

Division name

Department of Infectious Diseases

Zip code

260-8673

Address

1-8-1 Inohana, Chuo-ku, Chiba-shi, Chiba, Japan

TEL

043-226-2799

Email

ishiwada@faculty.chiba-u.jp


Public contact

Name of contact person

1st name Kenichi
Middle name
Last name Takeshita

Organization

Graduate School of Medicine, Chiba University

Division name

Department of Pediatrics

Zip code

260-8670

Address

1-8-1 Inohana, Chuo-ku, Chiba-shi, Chiba, Japan

TEL

043-226-2144

Homepage URL


Email

take1nek@yahoo.co.jp


Sponsor or person

Institute

Chiba university

Institute

Department

Personal name



Funding Source

Organization

Japan Agency for Medical Research and Development

Organization

Division

Category of Funding Organization

Japanese Governmental office

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Chiba university School of Medicine IRB

Address

1-8-1 Inohana, Chuo-ku, Chiba-shi, Chiba, Japan

Tel

043-222-7171

Email

inohana-rinri@chiba-u.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2019 Year 12 Month 02 Day


Related information

URL releasing protocol


Publication of results

Published


Result

URL related to results and publications


Number of participants that the trial has enrolled

42

Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2019 Year 11 Month 05 Day

Date of IRB

2019 Year 10 Month 04 Day

Anticipated trial start date

2019 Year 11 Month 05 Day

Last follow-up date

2022 Year 03 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information

investigate host immunogenecities of pneumococcus before and after receiving PCV13, and observe the incidence of invasive pneumococcal
disease for one year.


Management information

Registered date

2019 Year 12 Month 02 Day

Last modified on

2022 Year 06 Month 08 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000043619


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name